In 2024, do you consider isolated gain(1q) [not amp(1q)] to be a high-risk cytogenetic abnormality in multiple myeloma?

Topics: Hematologic Malignancies • Medical Oncology • Myeloma • NCI-CCC Tumor Board Question • University of Washington • NCI-CCC Myeloma Tumor Board Question • Multiple Myeloma

Most would argue that gain(1q) in combination with another high-risk feature constitutes ultra-high-risk multiple myeloma, and most would argue (with FORTE being a good example) that amp(1q) is a high-risk feature. What about patients who have exactly 3 copies of 1q and no other high-risk features?

Answer from: Medical Oncologist at Academic Institution

The brief answer from my standpoint is that some patients with 1q gain will have their disease behave high-risk and some will not. The longer answer...As the question alludes to, the presence of high-risk cytogenetic abnormalities and 1q gain should be considered high-risk (or even ul...

Comments

Medical Oncologist at University of Washington, Fred Hutchinson Cancer Research Center
Brilliantly stated - I love the unofficial idea of...

Medical Oncologist at Winship Cancer Institute of Emory University
I agree with what has been written to date. My onl...

Related Questions